711 related articles for article (PubMed ID: 18378028)
1. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy.
Pieters BR; van de Kamer JB; van Herten YR; van Wieringen N; D'Olieslager GM; van der Heide UA; Koning CC
Radiother Oncol; 2008 Jul; 88(1):46-52. PubMed ID: 18378028
[TBL] [Abstract][Full Text] [Related]
2. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer.
Li XA; Wang JZ; Jursinic PA; Lawton CA; Wang D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1251-7. PubMed ID: 15752907
[TBL] [Abstract][Full Text] [Related]
3. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous integrated intensity-modulated radiotherapy boost for locally advanced gynecological cancer: radiobiological and dosimetric considerations.
Guerrero M; Li XA; Ma L; Linder J; Deyoung C; Erickson B
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):933-9. PubMed ID: 15936580
[TBL] [Abstract][Full Text] [Related]
5. Treatment plan comparison between helical tomotherapy and MLC-based IMRT using radiobiological measures.
Mavroidis P; Ferreira BC; Shi C; Lind BK; Papanikolaou N
Phys Med Biol; 2007 Jul; 52(13):3817-36. PubMed ID: 17664579
[TBL] [Abstract][Full Text] [Related]
6. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate.
Luxton G; Hancock SL; Boyer AL
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):267-84. PubMed ID: 15093924
[TBL] [Abstract][Full Text] [Related]
7. Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy.
Hong TS; Tomé WA; Jaradat H; Raisbeck BM; Ritter MA
Acta Oncol; 2006; 45(6):717-27. PubMed ID: 16938815
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the dosimetric impact of non-exclusion of the rectum from the boost PTV in IMRT treatment plans for prostate cancer patients.
Kassim I; Dirkx ML; Heijmen BJ
Radiother Oncol; 2009 Jul; 92(1):62-7. PubMed ID: 19278745
[TBL] [Abstract][Full Text] [Related]
9. Persistently better treatment planning results of intensity-modulated (IMRT) over conformal radiotherapy (3D-CRT) in prostate cancer patients with significant variation of clinical target volume and/or organs-at-risk.
Fenoglietto P; Laliberte B; Allaw A; Ailleres N; Idri K; Hay MH; Moscardo CL; Gourgou S; Dubois JB; Azria D
Radiother Oncol; 2008 Jul; 88(1):77-87. PubMed ID: 18215434
[TBL] [Abstract][Full Text] [Related]
10. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.
King CR
Brachytherapy; 2002; 1(4):219-26. PubMed ID: 15062170
[TBL] [Abstract][Full Text] [Related]
11. Dosimetric comparison of high-dose-rate brachytherapy and intensity-modulated radiation therapy as a boost to the prostate.
Hermesse J; Biver S; Jansen N; Lenaerts E; Nickers P
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):269-76. PubMed ID: 19775833
[TBL] [Abstract][Full Text] [Related]
12. Optimization of radiation therapy for locally advanced adenoid cystic carcinomas with infiltration of the skull base using photon intensity-modulated radiation therapy (IMRT) and a carbon ion boost.
Schulz-Ertner D; Didinger B; Nikoghosyan A; Jäkel O; Zuna I; Wannenmacher M; Debus J
Strahlenther Onkol; 2003 May; 179(5):345-51. PubMed ID: 12740662
[TBL] [Abstract][Full Text] [Related]
13. Intraindividual comparison of conventional three-dimensional radiotherapy and intensity modulated radiotherapy in the therapy of locally advanced non-small cell lung cancer a planning study.
Marnitz S; Stuschke M; Bohsung J; Moys A; Reng I; Wurm R; Budach V
Strahlenther Onkol; 2002 Nov; 178(11):651-8. PubMed ID: 12426677
[TBL] [Abstract][Full Text] [Related]
14. Dose to bone marrow using IMRT techniques in prostate cancer patients.
Gershkevitsh E; Clark CH; Staffurth J; Dearnaley DP; Trott KR
Strahlenther Onkol; 2005 Mar; 181(3):172-8. PubMed ID: 15756521
[TBL] [Abstract][Full Text] [Related]
15. Comparing 3DCRT and inversely optimized IMRT planning for head and neck cancer: equivalence between step-and-shoot and sliding window techniques.
Longobardi B; De Martin E; Fiorino C; Dell'oca I; Broggi S; Cattaneo GM; Calandrino R
Radiother Oncol; 2005 Nov; 77(2):148-56. PubMed ID: 16260056
[TBL] [Abstract][Full Text] [Related]
16. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations.
Fuller DB; Naitoh J; Lee C; Hardy S; Jin H
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1588-97. PubMed ID: 18374232
[TBL] [Abstract][Full Text] [Related]
17. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
18. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study.
Pinkawa M; Fischedick K; Treusacher P; Asadpour B; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
Radiother Oncol; 2006 Jan; 78(1):41-6. PubMed ID: 16271785
[TBL] [Abstract][Full Text] [Related]
19. Normal tissue complication probability: does simultaneous integrated boost intensity-modulated radiotherapy score over other techniques in treatment of prostate adenocarcinoma.
Basu KS; Bahl A; Subramani V; Sharma DN; Rath GK; Julka PK
J Cancer Res Ther; 2009; 5(2):78-84. PubMed ID: 19542662
[TBL] [Abstract][Full Text] [Related]
20. Treatment planning for MRI assisted brachytherapy of gynecologic malignancies based on total dose constraints.
Lang S; Kirisits C; Dimopoulos J; Georg D; Pötter R
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):619-27. PubMed ID: 17869676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
